ERBB2 and gastric cancer: Notably, while the FDA approved dose of T DXd for HER2+ gastric cancer, GEJA monotherapy is 6.4 mg/kg, these results suggest that in combination with pembrolizumab and chemotherapy, a reduced dose of 5.4 mg/kg can achieve a higher confirmed ORR, potentially enhancing tolerability without compromising efficacy.